In subsequent sections, we will describe changes in TRPC6 that have been observed in human diseases and in animal disease models, and we will then review studies that test the hypothesis that knockout or inactivation of TRPC6 will slow the progression of kidney disease. Here, TRPC6 is linked to glycogen storage disease VI.